

INVEST  
IN ITALY



[madeinitaly.gov.it](http://madeinitaly.gov.it)

# BIO International Convention 2024

June 3-6, 2024 • San Diego Convention Center – San Diego, CA



## invest in tuscany



# Pharma Valley Digital Logistic Hub

## DESCRIPTION

### Field of activity and technology

Pharma Valley Logistic Digital Hub is an innovative high-tech logistics platform for pharmaceutical industry that will become a reference point for the whole of North Central Italy. It's developed on an area of 120 thousand square metres.

### Development stage

The logistic hub is under construction and it will start operations by 2024.

### Capital raised

The project is valued at € 80 M.




**Proposer**

*Pharma Valley RTI*

# Pharma Valley Digital Logistic Hub

## BUSINESS PROPOSAL

- systemic project with a public-private collaboration model, enabled by the network contract established between pharmaceutical companies and a multi-provider logistics model implemented with a panel of leading logistics providers;
- 100% life sciences logistics platform, in compliance with sector regulations, with a developed service portfolio that integrates basic logistics services with value-added services;
- advanced packaging services performed in the pharmaceutical factory, from the last step of production to the first step of distribution logistics to support future personalised medicine models;
- unique digital 5PL platform integrating data and information flows between companies, suppliers, infrastructure and consignees;
- automated bundling management between network companies' shipments;
- Import-export business accelerator thanks to the activation of customs fast corridors with the infrastructures of the territory;
- logistics model prepared for the management of both B2C and B2B flows, thanks to piece picking, pharmaceutical workshop and national and international distribution.
- structural reduction of transit times for national and air distribution, thanks to the creation of a DHL transit point adjacent to the platform and the activation of mid-week flights PISA-FRANKFURT.
- ESG-oriented logistics model that limits CO2 emissions thanks to consolidation, renewable energy systems, product circularity with reverse logistics services.



**Requested investment**

*To be evaluated with Pharma Valley RTI*

**Target investor**

*Pharma/Biotech Companies interested in evaluating to invest in Southern Europe*

# National Anti-Pandemic Center

## DESCRIPTION

### Field of activity and technology

The Biotechnopolo Foundation is a project of strategic national value. Its aim is to promote and develop applied research and innovation in the field of biotechnology and life sciences, including for the purpose of combating pandemics. Its role is to promote and coordinate study, research, technical and scientific development, technology transfer and the transfer of innovative processes for the purpose of combating pandemics. The Centro Nazionale Anti Pandemico (CNAP) focuses on the development and production of vaccines and monoclonal antibodies for the treatment of emerging epidemic and pandemic diseases. Biotechnopolo Foundation will make use of first and second level spoke centres and pathogen sequencing networks, ensuring the necessary interactions with centres involved in the development of vaccines according to the One Health model.

### Development stage

Biotechnopolo Foundation has been established on August 2022. It is fully operational

### Capital raised

€ 340 M up to 2026, National Pandemic Center

€ 37 M up 2024, Biotechnopolo Foundation



Proposer

*Biotechnopolo Foundation*


# National Anti-Pandemic Center

## BUSINESS PROPOSAL

The Foundation has the purpose of promoting and developing applied research and innovation in the field of biotechnologies and life sciences, also for countering pandemics. It has the function of promoting and coordinating study, research, technical and scientific development, technology transfer and innovative process transfer activities for the purpose of countering pandemics. The Foundation also functions as a pandemic hub through the National Pandemic Center.

In collaboration with other national and international entities, the Foundation encourages the implementation of programs for research, innovation and technology transfer to the production system in the field of biotechnological applications aimed at health protection based on a One Health approach. It also sustains the other project activities related to the implementation of the National Recovery and Resilience Plan (NRRP) interventions. This is done by promoting the coordination and integration of the NRRP measures.

The Foundation works in conjunction with institutions in the territories, including regional and local institutions and state territorial offices, the system of universities and other higher education and research institutions, both public and private, National Health Service entities, IRCCS (Scientific Institutes for Research, Hospitalization and Healthcare), ISS (Higher Institute of Health), INAIL (National Institute for Insurance against Accidents at Work), IZS (Experimental Animal Prophylactic Institutes) as well as the system of business and professional representation, with particular reference to the framework of the Siena life sciences ecosystem.



### Requested investment

*To be established with the Foundation, depending on the type of project*

### Target investor

*Biotech/Pharma Companies*

# Call for tender to attract investments in R&D

## DESCRIPTION

### Field of activity and technology

Invest in Tuscany launches a call for tender that will make available €10M to companies carrying out new R&D investments in Tuscany, with projects ranging from €1.5M to €3M.

### Development stage

The call for tender was launched in May 2024

### Capital raised

The total amount of the fund is €10M



**Proposer**

*Invest in Tuscany*

# Call for tender to attract investments in R&D

## BUSINESS PROPOSAL


The fund aims to incentivise investments in R&D up to the prototyping stages and with a high degree of tech innovation, supporting industrial research and experimental development activities.

The following categories of enterprises can apply obtaining a special rewarding in the evaluation process:

- Large Foreign Companies in collaboration with at least one SME;
- Foreign Mid Cap Companies, with or without collaboration with SMEs.

Aid intensity goes from 25% to 65% (capital contribution) of the total value of the project.

Rewards are provided for those Companies opening a new R&D facility in Tuscany.



**Requested investment**

*Projects from €1.5M to €3M*

**Target investor**

*All types of companies, including Life Sciences based businesses*